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A B S T R A C T
Childhood trauma is among the most potent contributing risk factors for depression and is associated with poor
treatment response. Hypothalamic-pituitary-adrenal (HPA) axis abnormalities have been linked to both child-
hood trauma and depression, but the underlying mechanisms are poorly understood. The present study aimed to
investigate the link between childhood trauma, HPA axis activity and antidepressant response in patients with
depression. As part of the Wellcome Trust NIMA consortium, 163 depressed patients and 55 healthy volunteers
were included in this study. Adult patients meeting Structured Clinical Interview for Diagnostic and Statistical
Manual Version-5 criteria for major depression were categorised into subgroups of treatment responder
(n = 42), treatment non-responder (n = 80) and untreated depressed (n = 41) based on current depressive
symptom severity measured by the 17-item Hamilton Rating Scale for Depression and exposure to antidepressant
medications established by Antidepressant Treatment Response Questionnaire. Childhood Trauma Questionnaire
was obtained. Baseline serum C-reactive protein was measured using turbidimetric detection. Salivary cortisol
was analyzed at multiple time points during the day using the ELISA technique. Glucocorticoid resistance was
defined as the coexistence of hypercortisolemia and inflammation. Our results show that treatment non-re-
sponder patients had higher exposure to childhood trauma than responders. No specific HPA axis abnormalities
were found in treatment non-responder depressed patients. Untreated depressed showed increased diurnal
cortisol levels compared with patients on antidepressant medication, and higher prevalence of glucocorticoid
resistance than medicated patients and controls. The severity of childhood trauma was associated with increased
diurnal cortisol levels only in individuals with glucocorticoid resistance. Therefore, our findings suggest that the
severity of childhood trauma experience contributes to a lack of response to antidepressant treatment. The
effects of childhood trauma on increased cortisol levels are specifically evident in patients with glucocorticoid
resistance and suggest glucocorticoid resistance as a target for the development of personalized treatment for a
subgroup of depressed patients with a history of childhood trauma rather than for all patients with resistance to
antidepressant treatment.
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Major depressive disorder (MDD) is a debilitating condition and the
most common psychiatric disorder with more than 300 million people
affected worldwide according to the World Health Organisation.
Although there are effective antidepressants available, more than one
third of depressed patients do not respond to conventional treatments
(Cleare et al., 2015, Ferrari et al., 2013). Ongoing studies aim to im-
prove our understanding of the biological mechanisms underlying the
causality, development and pathogenesis of depression in order to de-
velop new, more successful and personalized treatment strategies. With
growing advances in psychoneuroimmunology research, extensive evi-
dence suggests the importance of abnormal brain-endocrine-immune
interaction and dysregulated neuroendocrine and neuroimmune re-
sponse in the pathogenesis of depression (Miller and Raison, 2016). As
shown by the findings from several large population samples and
clinical meta-analyses, a significant proportion of depressed patients
exhibit hyperactivation of the hypothalamic–pituitaryadrenal (HPA)
axis thus increased secretion of the stress hormone cortisol as well as
elevated levels of inflammatory biomarkers (Haapakoski et al., 2015,
Howren et al., 2009, Perrin et al., 2019, Valkanova et al., 2013,
Zunszain et al., 2011). It has been suggested that such disturbances are
due to the dysfunction of glucocorticoid receptors (GR), and therefore
an impairment in cortisol to mediate HPA axis negative feedback and
regulate its own production, and to promote anti-inflammatory re-
sponse. Indeed, attenuated glucocorticoid responsiveness, so called
glucocorticoid resistance, has been consistently observed in MDD pa-
tients presenting coexistence of hypercortisolemia and inflammation
(Pariante, 2017, Perrin et al., 2019, Stewart et al., 2009).
Early-life traumatic experiences including childhood physical,
sexual and emotional abuse and/or neglect are among the most potent
contributing risk factors for increased diathesis for major depression in
adulthood (Chapman et al., 2004, Heim et al., 2010). Early exposure to
life stress has been linked to increased inflammation (Baldwin et al.,
2018, Baumeister et al., 2016, Danese et al., 2008) and HPA axis ab-
normalities such as a dysregulation of the glucocorticoid-mediated
negative feedback and an increased cortisol reactivity in adulthood
(Harkness et al., 2011, Lu et al., 2016). These neuroendocrine and
neuroimmune alterations secondary to childhood traumatic experiences
significantly increase vulnerability to the lifetime stress reactivity and
subsequent risk for the onset of depressive episodes (Heim et al., 2008,
Nemeroff and Binder, 2014).
The heterogeneous nature of MDD with multifactorial aetiological
and pathophysiological mechanisms involved, makes treatment more
challenging. To date, relatively few investigations have been trying to
address this issue and proposing predictors of treatment response in
depression. Childhood trauma and maltreatment has been previously
associated with poor treatment response to antidepressant pharma-
cotherapies (Kaplan and Klinetob, 2000, Nanni et al., 2012, Williams
et al., 2016). The findings supporting the association between HPA axis
hyperactivity and lack of response to treatment in depression are less
consistent. While some studies reveal that treatment non-responder
depression is associated with hypercortisolemia and elevated in-
flammation in the presence of glucocorticoid resistance (Carvalho et al.,
2010, Carvalho et al., 2008) and that depressed patients with higher
inflammation are less responsive to standard antidepressant treatments
(Carvalho et al., 2013, Kopschina Feltes et al., 2017); a recent meta-
analysis does not support hyperactivation of HPA axis as a predictor for
antidepressant treatment response (Fischer et al., 2017). No previous
study has investigated in the same sample of patients the association
between childhood trauma and HPA axis with antidepressant treatment
response.
Considering the costs and challenges for patients and society asso-
ciated with treatment-resistance in depression, it is important to iden-
tify specific and reliable biomarkers predictive of antidepressant effi-
cacy as well as to distinguish those subgroups of depressed patients
exhibiting physiological abnormalities affecting their therapeutic re-
sponse in order to develop new strategies to achieve successful clinical
treatment of depression. Therefore, the present study aims to in-
vestigate 1) whether experience of childhood trauma is associated with
lack of response to antidepressant treatment, 2) whether abnormalities
in HPA axis activity (assessed as diurnal cortisol, cortisol awakening
response, and glucocorticoid resistance) are associated with lack of
response to antidepressant treatment, and 3) whether the experience of
childhood trauma is associated with specific abnormalities in HPA axis
activity in patients with depression.
2. Materials and methods
2.1. Subjects
The current cross-sectional study was conducted as part of the
BIODEP (BIOmarkers in DEPression) Wellcome Trust
Neuroinflammation Consortium, NIMA (Neuroimmunology of Mood
Disorders and Alzheimer’s disease), an observational non-interventional
study (Chamberlain et al., 2019). Volunteers aged 25–50 years were
recruited by a network of clinical research centres in the UK including
Brighton, Cambridge, Glasgow, King’s College London and Oxford. The
study participants consisted of patients with a current diagnosis of MDD
according to Diagnostic and Statistical Manual Version 5 (DSM-5)
(American Psychiatric Association, 2013) recruited from mental health
and primary national health services as well as healthy adults. Patients
were categorised by monoaminergic antidepressant (MA) exposure and
therapeutic response at the time of the assessment. Healthy controls
were sampled to match the patient group for age and sex. The study was
approved by Research Ethics Committee (National Research Ethics
Service East of England, Cambridge Central, UK) and conducted ac-
cording to the Declaration of Helsinki. Written informed consent was
obtained from all participants prior to performing any study related
activity including eligibility screening examination.
2.2. Clinical measures
Diagnosis of MDD and other psychiatric disorders were ascertained
by Structured Clinical Interview for DSM-5 (Spitzer et al., 1996). The
severity of depressive symptoms was assessed using 17-item Hamilton
Rating Scale for Depression (HAM-D17) (Hamilton, 1960). The exposure
to antidepressant medications was established by Antidepressant
Treatment Response Questionnaire (Desseilles et al., 2011). Patients
were categorised into three subgroups: treatment responder patients
who were not depressed (HAM-D <7) after at least 6 weeks of treat-
ment with a monoaminergic antidepressant (DEP-MA+); treatment
non-responder depressed patients who were depressed (HAM-D >13)
after at least 6 weeks of treatment with one or more monoaminergic
antidepressants (DEP+MA+); and untreated depressed patients who
were depressed (HAM-D >17) but had not been treated with mono-
aminergic antidepressants in the previous 6 months (DEP+MA−).
Healthy volunteers had no history of depression requiring treatment
with either monoaminergic antidepressants or other clinical interven-
tions including psychotherapy (DEP−MA−).
Exclusion criteria were applied for participants with life time bi-
polar or non-affective psychotic disorder, sufferers from a medical
condition associated with systemic and/or CNS inflammation (such as
immunological disorders, cardiovascular disorders, malignancies, re-
cent or current infection confirmed by screening interview and further
through the results of the cell blood count, brain disorders) and those
with concurrent use of any medication likely to compromise the in-
terpretation of immunological data (such as use of corticosteroids, anti-
histamines and anti-inflammatory drugs), current substance use dis-
orders for the last 6 months, participants in clinical trial of an in-
vestigational drug within the last 12 months, breast feeding or pregnant
women.
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Following a semi structured clinical interview, demographic char-
acteristics of the participants were documented. Height and weight
were measured for body mass index (BMI) calculation. Participants
were also assessed for the childhood trauma by means of Childhood
Trauma Questionnaire (CTQ) to measure the severity of different types
of childhood trauma including Emotional Abuse, Emotional Neglect,
Physical Abuse, Physical Neglect and Sexual Abuse (Bernstein et al.,
1994). The Beck Depression Inventory II (BDI-II) (Beck et al., 1996) was
also completed and followed by collection of fasting peripheral venous
blood between 8:00–10:00am. Participants were then issued with the
materials and instruction for collecting the saliva samples.
2.3. Peripheral C-reactive protein measurements
The nonspecific acute phase reactant, hsCRP was measured as the
most reliable biomarker of on-going inflammation implicated in pa-
thophysiology of depression and its response to treatment (Haroon
et al., 2018, Miller and Raison, 2016). Recent research has confirmed
that hsCRP is a clinically valuable inflammatory marker, both periph-
eral and central, and can serve as a proxy for cytokines and other in-
flammatory mediators, which are more difficult to measure in the clinic
(Felger et al., 2018, Miller et al., 2017). The CRP analysis has been
described in detail in (Chamberlain et al., 2019) but briefly, the blood
samples were collected in clot activator containing tubes for measure-
ments of hsCRP. The samples were allowed to coagulate for 30–60 min
then centrifuged at 1600 Relative Centrifugal Force (RCF) for 15 min.
The serum samples were separated and transported to a central la-
boratory (Q2 Solutions) where analysed on the day of receipt. Samples
were exposed to anti-CRP-antibodies on latex particles, and the increase
in light absorption due to complex formation was used to quantify
hsCRP levels, using Turbidimetry on Beckman Coulter AU analyzers.
Inter and intra-assay co-efficient of variations were <10%. The Clinical
Reporting Range (CRR) for the hsCRP assay was 0.2–9999.9 mg/L.
2.4. Salivary cortisol measurements
For cortisol measurements, salivary sampling has been the preferred
method over blood sampling in clinical studies and research settings as
being an easy to employ, inexpensive, non-invasive and stress-free way
to collect samples. A high correlation between plasma and salivary
cortisol has been reported in studies investigating HPA axis function
indicating that salivary cortisol measurements are a reliable marker of
HPA axis assessment (Petrowski et al., 2013). Saliva samples were
collected from participants according to our previously published pro-
cedure (Mondelli et al., 2010, Nikkheslat et al., 2015). Using salivette
sampling devices (Sarstedt, Leicester, UK), the self-collection of samples
was carried out at home at 6 time points throughout the day; at awa-
kening, 15, 30 and 60 min after awakening, at 12 pm and at 8 pm.
Individuals who described problems during sample collection in the
self-recorded questionnaire provided, or who did not respect the time-
intervals required, were removed from the analysis. The current study
includes those participants who completed saliva sample collections
accurately and provided adequate amount of sample for measurements
of cortisol. Salivary cortisol levels were measured using a commercially
available high sensitivity salivary cortisol enzyme immunoassay kit
(Salimetrics). SoftMax Pro 4.8 software was used to calculate the cor-
tisol values, following a 4-parameter fit. The analytical sensitivity was
set to 0.19 nmol/l. Inter and intra-assay co-efficient of variations
ranged 8–10% and 6–10%, respectively. To investigate the activity and
responsiveness of the HPA axis, we first compared the mean values at
the various time points of salivary cortisol collection; and secondly, we
calculated the area under the curve with respect to the increase (AUCi)
for the cortisol awakening response using the 4 time points of 0, 15, 30,
and 60 min after awakening; and the area under the curve with respect
to the ground (AUCg) for the diurnal cortisol using the 3 main points
over the whole day: awakening, noon 12 pm and 8 pm. AUCg indicates
the total amount of cortisol produced thus represents the HPA axis
overall activity during the day. AUCi measures the variation (either
positive or negative) in cortisol concentration thus signifies the HPA
axis reactivity and response to the stress of awakening. The formulas for
the calculations of the AUC were derived from the trapezoidal formula
introduced by Pruessner (Pruessner et al., 2003).
Glucocorticoid resistance was defined as coexistence of increased
cortisol production and elevated hsCRP levels as a clinical biomarker of
inflammation that indicates an impaired ability of cortisol to exert its
anti-inflammatory effect. Therefore, individuals exhibiting the evidence
for the presence of glucocorticoid resistance were characterised as those
who had both high hsCRP >3 mg/L, which is indicative of an increased
inflammation based on widely accepted cut-off points (Pearson et al.,
2003) and high diurnal cortisol levels, AUCg >50 nmol/L considering
overall sample median. Subjects with the hsCRP values more than
10 mg/L representing the presence of acute inflammation were ex-
cluded from the analysis.
2.5. Data analysis
All statistical analyses were performed using SPSS software version
24.0. All data were tested for suitability for parametric or non-para-
metric analysis. For comparisons of the four study groups, including the
three groups of MDD patients and the group of controls, we performed
one-way ANOVA analysis or Kruskal-Wallis test, where the data vio-
lated parametric assumptions confirmed by Shapiro-Wilk test. Tukey’s
HSD test was used for post-hoc analysis for the pairwise group differ-
ences. Cohen’s d was reported for the effect size of hsCRP, CTQ and
cortisol in each clinical group compared to healthy controls.
Dichotomous variables including gender and glucocorticoid resistance
were compared using Chi-square test. Correlations were assessed using
Pearson’s product moment correlation. Mediation analysis was per-
formed using the PROCESS macro. Linear Regression was carried out to
investigate the association between childhood trauma and diurnal
cortisol in both glucocorticoid resistance and non-resistance groups. A
two-way ANOVA with repeated measures was used to determine the
differences in salivary cortisol at different time points of the awakening
response and during the day among the four groups. General linear
model (ANCOVA) and hierarchical multiple regression were performed
for taking into account the effect of covariates including BMI, age and




A total of 218 participants who provided saliva samples for cortisol
measurements were included in this study. The sociodemographic and
clinical characteristics of the study sample is presented in Table 1.
Treatment responder, treatment non-responder and untreated de-
pressed patients and controls showed similar age range (One-way
ANOVA, F = 1.05, p > 0.05) and distribution of gender among the
groups (Chi-square, χ2 = 0.15, p > 0.05). HAM-D scores were sig-
nificantly different between each group compared with other groups, as
confirmed by the pairwise post hoc analysis (Table 1) (One-way
ANOVA, F = 642.01, p < 0.001). BDI-II was positively correlated with
the HAM-D17 (Pearson, r = 0.757, p < 0.0001). Overall, patients and
controls differed significantly on their BMI (One-way ANOVA,
F = 2.96, p < 0.05); however, running the post hoc analysis, the dif-
ference was only found between treatment responders and controls
(p = 0.047). Compared with healthy adults, depressed groups exhibited
an increased level of inflammation as indicated by CRP marker
(Table 1) (One-way ANOVA, F = 3.9, p < 0.01). Patients also appeared
to have experienced greater childhood trauma when each group was
compared with controls (Table 1) (One-way ANOVA, F = 12.62,
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p < 0.001).
3.2. Childhood trauma, depression and antidepressant response
Depressed individuals had significantly higher exposure to child-
hood trauma when compared with healthy adults (U = 2089.50,
z = −5.919, p < 0.0001), and this was also true when each subgroup
of patients was compared with controls (Table 1). Comparing the two
groups of patients under medication, treatment non-responder de-
pressed patients revealed significantly higher CTQ total scores than
treatment responders (U = 1261.00, z = −2.259, p = 0.024). Ex-
amining the potential mediating role of cortisol and hsCRP on the as-
sociation between childhood trauma and adulthood depressive symp-
toms in treatment non-responder depressed patients indicated that the
association was not mediated by the effect of cortisol (Direct effect of
CTQ on BDI-II: B = 0.285, p = 0.0038 and indirect effect via AUCg:
p > 0.05, CI −0.294, 0.014; direct effect of CTQ on AUCg: B = 0.0007,
p = 0.998, and AUCg on BDI-II: B = −0.024, p = 0.423) or hsCRP
(Direct effect of CTQ on BDI-II: B = 0.204, p = 0.0048 and indirect
effect via hsCRP: p > 0.05, CI −0.031, 0.026; direct effect of CTQ on
hsCRP: B = 0.012, p = 0.459, and hsCRP on BDI-II: B = 0.398,
p = 0.417) in these patients.
3.3. Cortisol production and glucocorticoid resistance
The repeated measures ANOVA comparing the salivary cortisol at
different time points among the groups showed no significant differ-
ences in the levels of cortisol at each time point between three groups of
patients with depression (treatment responder, treatment non-re-
sponder and untreated patients) and controls, for both the first hour
post awakening (Fig. 1a) (Two-way ANOVA for the between-group ef-
fect, F(3,3) = 0.793, p = 0.50), and during the day (Fig. 1b) (Two-way
ANOVA for the between-group effect, F(3,2) = 0.137, p = 0.94). The
results from calculating the AUCi (nmol·min/L) for the cortisol awa-
kening response (Fig. 1a) by measuring the variation (either positive or
negative) in cortisol concentration revealed no differences in the HPA
axis reactivity and response to the stress of awakening among the
groups (Kruskal-Wallis, H = 2.83, p = 0.42) (Table 1).
The AUCg for the diurnal cortisol (nmol·hr/L) (Fig. 1b), indicative of
the HPA axis overall activity by measuring the total amount of cortisol
concentrations, was significantly different among the groups (Kruskal-
Wallis, H = 8.721, p = 0.033); the post-hoc analyses revealed
Table 1




Non-responder (2) (n = 80)
Untreated
Depressed (3) (n = 41)
Healthy
Control (4) (n = 55)
Test and Significance
*Post-hoc Analysis
Age, years (±SD) 36 (±7.8) 36.8 (±7.7) 35.6 (±8.5) 34.5 (±7.2) F = 1.05, p = 0.37
(95% CI) (33.5–38.4) (35.1–38.6) (32.8–38.2) (32.5–36.4)
Gender, female n (%) 29 (69.0%) 57 (71.3%) 28 (68.3%) 38 (69.1%) χ2 = 0.15, p = 0.99
BMI (kg/m2) (±SD) 27.7 (±5.2) 27.1 (±6.9) 25.8 (±4.5) 24.6 (±4.8) F = 2.96, p = 0.03
(95% CI) (26.1–29.3) (25.5–28.6) (24.3–27.2) (23.3–26.0) *1 > 4
HAM-D17 score (±SD) 3.6 (±2.9) 18.1 (±3.8) 20.3 (±3.2) 0.7 (±1.1) F = 642.01, p < 0.001
(95% CI) (3.0–4.2) (17.2–18.9) (19.3–21.3) (0.4–1.0) *1, 2, 3 > 4; 2, 3 > 1; 3 > 2
BDI-II score (±SD) 10.7 (±9.8) 26.5 (±10.9) 23.8 (±9.3) 2.3 (±4.1) F = 91.53, p < 0.001
(95% CI) (7.6–13.7) (24.1–28.9) (20.9–26.7) (1.2–3.4) *1, 2, 3 > 4; 2, 3 > 1
CRP (mg/L) (±SD) 2.4 (±2.5) 2.2 (±2.4) 2.0 (±2.3) 1.1 (±1.1) F = 3.91, p = 0.009
(95% CI) (1.6–3.2) (1.7–2.8) (1.2–2.7) (0.8–1.4) *1, 2 > 4
ES Cohen’s d vs HC 0.65 0.58 0.45
SC (nmol/L)
SC Awakening (±SD) 9.2 (±4.1) 9.7 (±7.5) 9.1 (±4.7) 9.6 (±5.8) F = 0.16, p = 0.93
(95% CI) (7.9–10.5) (8.1–11.4) (7.6–10.5) (8.1–11.2)
SC 15 min (±SD) 10.4 (±4.6) 11.8 (±7.1) 11.3 (±5.6) F = 0.61, p = 0.61
(95% CI) (8.9–11.8) (10.3–13.5) (9.5–13.0) (10.2–13.2)
SC 30 min (±SD) 10.2 (±4.8) 11.8 (±6.4) 12.3 (±6.4) 12.0 (±5.7) F = 1.10, p = 0.35
(95% CI) (8.7–11.7) (10.4–13.2) (10.3–14.3) (10.5–13.6)
SC 60 min (±SD) 7.4 (±3.7) 8.9 (±6.0) 9.6 (±5.3) 9.9 (±6.2) F = 1.82, p = 0.14
(95% CI) (6.2–8.5) (7.6–10.3) (7.9–11.3) (8.2–11.6)
SC 12 noon (±SD) 4.1 (±2.8) 4.3 (±3.8) 5.4 (±2.9) 4.5 (±3.0) F = 1.43, p = 0.24
(95% CI) (3.2–4.9) (3.5–5.1) (4.5–6.3) (3.7–5.4)
SC 8 pm (±SD) 2.2 (±2.9) 2.2 (±3.3) 2.2 (±3.0) 2.1 (±1.6) F = 0.04, p = 0.99
(95% CI) (1.3–3.1) (1.5–3.0) (1.3–3.2) (1.6–2.5)
AUCi (nmol·min/L) 12.5(±178.9) 65.1 (±211.2) 113.6 (±323.5) 80.06 (±295.9) H = 2.83, p = 0.42
(±SD) (95% CI) (−43.2 to 68.2) (17.8–112.5) (11.5–215.7) (−1.5 to 161.6)
AUCg (nmol·h/L) 53.2 (28.9) 54.4 (38.9) 60.8 (25.2) 59.3 (26.5) H = 8.72, p = 0.03
(±SD) (95% CI) (44.2–62.2) (45.7–63.1) (52.9–68.8) (52.0–66.6) *3 > 1,2
CTQ score Total (±SD) 42.6 (±19.1) 47.8 (±16.9) 53.0 (±16.5) 34.2 (±11.5) F = 12.62, p < 0.001
(95% CI) (36.7–48.6) (44.0–51.5) (47.8–58.2) (31.0–37.3)
ES Cohen’s d vs HC 0.54 0.94 1.32 *1, 2, 3 > 4; 2, 3 > 1
Emotional Abuse (±SD) 9.6 (±5.0) 11.9 (±5.4) 13.6 (±5.4) 6.9 (±2.8) F = 18.97, p < 0.001
(95% CI) (8.1–11.2) (10.7–13.1) (11.9–15.3) (6.1–7.6)
Emotional Neglect (±SD) 11.5 (±5.0) 14.2 (±5.3) 15.5 (±5.0) 9.1 (±3.5) F = 18.29, p < 0.001
(95% CI) (9.9–13.0) (13.0–15.3) (13.9–17.1) (8.2–10.1)
Physical Abuse (±SD) 6.8 (±3.6) 7.0 (±3.5) 7.4 (±3.3) 6.2 (±5.0) F = 1.09, p = 0.36
(95% CI) (5.7–7.9) (6.3–7.8) (6.4–8.4) (5.3–7.1)
Physical Neglect (±SD) 7.8 (±3.7) 7.9 (±3.4) 8.7 (±3.0) 6.4 (±2.5) F = 4.69, p = 0.004
(95% CI) (6.6–8.9) (7.1–8.6) (7.8–9.6) (5.7–7.0)
Sexual Abuse (±SD) 6.9 (±5.0) 6.8 (±4.4) 7.8 (±5.7) 5.6 (±2.4) F = 1.96, p = 0.12
(95% CI) (5.4–8.5) (5.9–7.8) (6.0–9.6) (5.0–6.3)
AUCg = Area Under the Curve ground, AUCi = Area Under the Curve increase, BDI = Beck depression inventory, BMI = body mass index, CRP = C-reactive
protein, CTQ = Childhood Trauma Questionnaire, HAM-D17 = Hamilton Depression Rating Scale 17 for Depression, ES = Effect Size, HC = Healthy Control,
SC = Salivary Cortisol
* Tukey’s HSD pairwise group significant differences (p < 0.05).
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significant difference between untreated depressed and treatment re-
sponder (U = 630.00, z = −2.104, p = 0.035, ES Cohen’s d = 0.28)
and between untreated depressed and treatment non-responder patients
(U = 1192.50, z = −2.451, p = 0.014, ES Cohen’s d = 0.2) (Table 1).
Indeed, combining the two groups of patients who were on medication
(both treatment responder and treatment non-responder) showed sig-
nificantly lower diurnal cortisol production when compared with un-
treated depressed individuals (U = 1822.50, z = −2.595, p = 0.009).
Investigating the presence of glucocorticoid resistance, MDD pa-
tients showed higher prevalence of glucocorticoid resistance as com-
pared with healthy adults (Chi-square, χ2 = 3.726, p = 0.05). Further
analysis revealed that depressed patients who were untreated had sig-
nificantly higher proportion of individuals (26.8%) with glucocorticoid
resistance (diurnal cortisol secretion above median and hsCRP >3 mg/
L), than both treatment responder (11.9%) and treatment non-re-
sponder patients (6.3%), as well as controls (3.6%) (Chi-square,
χ2 = 15.948, p = 0.001) (Fig. 2).
3.4. Association of childhood trauma with cortisol and glucocorticoid
resistance
The severity of childhood trauma was not found to be associated
with higher cortisol levels in depressed patients (p > 0.05). However,
in individuals with glucocorticoid resistance, childhood trauma was
positively associated with greater diurnal cortisol output in adulthood
(F = 34.775, p < 0.0001), as opposed to individuals with no gluco-
corticoid resistance (F = 1.278, p = 0.26) (Table 2).
3.5. Covariate analysis
The effect of BMI as a confounder has been analysed on serum
hsCRP, cortisol awakening response, diurnal salivary cortisol and the
statistically significant results remained unchanged. The regression
model has been also controlled for age, gender and BMI and the out-
come remained unchanged.
4. Discussion
Our results show that depressed individuals, regardless of treatment
response, had more experience of childhood trauma than healthy sub-
jects. When considering the response to antidepressant medications,
treatment non-responder patients had higher exposure to childhood
trauma compared with responders. We did not find any specific HPA
axis activity abnormality to be associated with non-response to the
treatment. However, depressed patients who were on antidepressant
medication showed lower total diurnal cortisol production compared
with untreated patients. In addition, we found that the untreated group
had higher proportion of individuals presenting with glucocorticoid
resistance than medicated depressed patients and controls. Severity of
childhood trauma was associated with increased diurnal cortisol levels
only in individuals with glucocorticoid resistance.
Cortisol is the primary end-product and the main peripheral marker
of the HPA axis. Studies reveal mixed results when looking at the link
between depression and the HPA axis as a principal endocrinological
stress response system, with most findings suggesting the presence of
HPA axis hyperactivation characterised by increased cortisol con-
centrations in almost half of MDD patients (Pariante 2017, Perrin et al.,
2019, Herbert, 2013, Vreeburg et al., 2009). However, a systematic
review and meta-analysis detected only a small difference in salivary
cortisol levels between depressed patients and controls, and re-
commended the interpretation of results with caution due to a sub-
stantial overlap between values in the two groups, presence of random
errors and bias, and large heterogeneity between studies (Knorr et al.,
2010). According to another meta-analysis, the degree of hypercorti-
solemia in depression may vary considerably depending on the type of
depression and the age of patients included in the studies. The authors
concluded that greater cortisol differences between depressed and non-
depressed were mostly reported in older patients and also more in
hospitalised individuals than outpatients (Stetler and Miller, 2011).
These outcomes may explain no differences in cortisol awakening re-
sponse and diurnal cortisol levels among the groups (Fig. 1) of our
current study, which was mainly focussing on a population of younger
outpatient adults. These findings further suggest the HPA axis ab-
normalities may be more pronounced in specific groups of patients or
may reflect more severe depressive states (hospitalized patients).
The investigation on the association between antidepressant treat-
ment and HPA axis activity by means of measuring AUCg for the diurnal
cortisol output revealed lower cortisol levels in medicated depressed
patients, both treatment responder and treatment non-responder, than
those who were untreated. It appears that antidepressant medications,
rather than depression status and regardless to the responsiveness, in-
fluence cortisol production in patients with depression. A recent meta-
analysis assessed HPA axis functioning as predictor of depressive re-
sponse and reported no differences in cortisol secretion between
treatment responders and non-responders. Following the meta-regres-
sion analysis, the study revealed that compared with responders, the
hypercortisolemia in non-responders were demonstrated only in those
studies with no report on sample handling, no account for controlling
for age, and excluding comorbidities (Fischer et al., 2017). While al-
tered HPA axis alone may not be a robust marker for predicting treat-
ment response, the findings supporting the effect of antidepressants in
Fig. 1. Mean salivary cortisol levels for the cortisol awakening response (a) and
diurnal cortisol secretion (b) in patients with depression (treatment responder,
treatment non-responder and untreated depressed groups) and healthy subjects
(Two-way ANOVA, p > 0.05).
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normalizing HPA axis dysregulation in depression cannot be overlooked
(Pariante, 2017, Pariante and Lightman, 2008). Indeed, it has been
evident that antidepressants, apart from their classic mechanism of
action on the neurotransmitter system, have a distinct role in normal-
ising HPA axis abnormalities by directly enhancing GR function and
expression, thus promoting cortisol-mediated negative feedback reg-
ulation of the axis (Anacker et al., 2011a, Nikkheslat et al., 2017). The
mechanism of antidepressants action on GR and activation of gluco-
corticoid molecular pathways in various target tissues provides also
other putative therapeutic related effects for example, by increasing
hippocampal neurogenesis and reducing peripheral inflammation
(Anacker et al., 2011b, Anacker et al., 2013, Carvalho et al., 2010).
Our results revealed that depressed individuals were more likely to
exhibit evidence of glucocorticoid resistance (coexistence of high cor-
tisol and high hsCRP), and that untreated patients specifically had
greater proportion of individuals presenting glucocorticoid resistance
than medicated depressed patients and controls (Fig. 2). Immune acti-
vation and inflammation have been consistently reported in depressed
patients (Dowlati et al., 2010, Haapakoski et al., 2015, Huang et al.,
2019, Valkanova et al., 2013). Regulation of inflammatory response is
one of the key roles of glucocorticoids. The notion of glucocorticoid
resistance in relation to inflammation has been studied extensively over
the last two decades (Pariante, 2017). Insights into molecular me-
chanisms underlying inflammatory dysregulation in depression dis-
closed a bidirectional association between inflammation and GR. Pro-
longed inflammation and activated cytokine-signalling pathway
interact with GR-signalling pathway leading to a decrease in GR sen-
sitivity. A dysfunctional GR in turn shows an impaired responsiveness
to cortisol and a reduced ability to perform anti-inflammatory action
(Pace et al., 2007, Zunszain et al., 2011). Interestingly, it has been
demonstrated that some antidepressants are able to improve GR func-
tion (Carvalho et al., 2010, Carvalho and Pariante, 2008, Pariante et al.,
1997) and reverse glucocorticoid resistance (Pariante et al., 2012,
Pariante et al., 2004). The findings, which support our result showing
less prevalence of glucocorticoid resistance in medicated depressed
groups, both treatment responder and treatment non-responder, suggest
that antidepressant drugs, regardless of whether depressive symptoms
persist, may exert anti-inflammatory effects through improving the ef-
fectiveness of cortisol response.
Studies on treatment resistance depression also demonstrated ele-
vated inflammatory response in the context of HPA axis hyperactivation
and hypercortisolemia in severely depressed non-responder inpatients
(Carvalho et al., 2008). The presence of glucocorticoid resistance was
further confirmed on the same group of patients by in vitro evaluation of
GR on their peripheral blood mononuclear cells that were unable to
respond to synthetic glucocorticoid, dexamethasone, during immune
challenge by bacterial lipopolysaccharide (Carvalho et al., 2010). Fol-
lowing the evidence suggesting the association of inflammation with
depression and lack of clinical therapeutic benefit of antidepressants
(Carvalho et al., 2013), recent research is focusing on targeting in-
flammation and use of anti-inflammatory medications in treatment of
depression for those subgroups of patients who may require alternative
Fig. 2. Patients with depression who were untreated
had a significantly higher proportion of individuals
with glucocorticoid (GC) resistance (hypercortiso-
lemia and high CRP) compared with medicated pa-
tients with depression (both treatment responder and
treatment non-responder) as well as with controls (χ2
= 15.948, p < 0.01).
Table 2
Linear regression for association between childhood trauma (CTQ total score) and diurnal cortisol production (AUCg of diurnal cortisol nmol·h/L) in individuals with
glucocorticoid resistance compared with those with no glucocorticoid resistance.
R R2 Adjusted R2 F 95% CI B Beta p value
GC Non-Resistance 0.082 0.007 0.001 1.278 −0.436 to 0.118 −0.159 −0.082 0.260
GC Resistance 0.790 0.623 0.606 34.775 0.521–1.088 0.805 0.790 <0.0001
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or adjuvant therapeutic strategies (Husain et al., 2017, Kopschina Feltes
et al., 2017, Miller and Raison, 2016). In our study, although the
treatment non-responder group exhibit elevated inflammation and
presence of glucocorticoid resistance in a subset of patients, we have
not found significantly higher levels of hsCRP, cortisol and GR re-
sistance compared with treatment responders; this finding would sug-
gest involvement of other pathophysiological mechanisms and aetio-
logical factors associated with their response to treatment, that is
important to take into account, considering the heterogeneous nature of
MDD.
Childhood maltreatment as one of the most potent risk factors for
development of depression adversely affects the course of illness and
response to the antidepressant treatment (Kaplan and Klinetob, 2000,
Williams et al., 2016). A meta-analysis looking at both epidemiological
and clinical studies revealed that childhood maltreatment follows a
greater risk of developing both recurrent and persistent depressive
episodes in depressed adults and with poorer treatment outcome com-
pared with depressed individuals without a history of childhood mal-
treatment (Nanni et al., 2012). Testing the hypothesis on the associa-
tion between childhood trauma, depression and treatment response in
line with mounting evidence documented up to date, the current study
population of depressed patients have also shown more experience of
childhood trauma compared with healthy controls. When the response
to antidepressant medications was considered, treatment non-responder
individuals had indeed higher exposure to childhood trauma than
treatment responders. In addition, the association between childhood
trauma and adulthood depressive symptoms in treatment non-re-
sponder patients was not found to be mediated by the effect of cortisol
or hsCRP. These findings highlight the importance of early preventive
and therapeutic interventions as well as enquiring information about
childhood trauma as a routine clinical assessment of depression in order
to identify individuals at higher risk of poor response to treatment.
However, establishing alternative and more effective treatment options
requires comprehensive understanding of the specific physiological
phenotype and targeting those responsible biological abnormalities in
this depressed group. It is important to note that not all individuals who
are exposed to trauma in their childhood would develop depression
later in life and some even demonstrate resilience to depression when
exposed to additional stressors throughout life; this suggests the pre-
sence of opposite biological responses across different individuals
probably mediated by genetic and epigenetic factors (Heim et al., 2009,
Monroe and Reid, 2008).
Recently, more research has attempted to identify the pathophy-
siological mechanisms underlying development of depression triggered
by early life stress and to establish the existence of biologically distin-
guishable subtypes of depression associated with childhood trauma and
to predict individuals who would be responsive to treatment (Harkness
et al., 2011, Heim et al., 2008, Lu et al., 2016). Indeed, early exposure
to life stress has been linked to neuroendocrine and neuroimmune
changes including alterations in HPA axis activity (Harkness et al.,
2011, Lu et al., 2016), increased cortisol reactivity and pro-in-
flammatory state in adulthood (Baumeister et al., 2016, Danese et al.,
2007). In our attempt to investigate HPA axis function and inflamma-
tion as underlying physiological mechanisms linking childhood trauma
with depression and treatment response, we have found that (Table 2)
the severity of childhood trauma was associated with higher cortisol
levels only in individuals exhibiting glucocorticoid resistance but not in
those without glucocorticoid resistance or the overall depressed sub-
jects. These findings indicate different neuroendocrine and neu-
roimmune responses to childhood trauma in individuals with depres-
sion. Based on evidence suggesting that neuroendocrine and
neuroimmune alterations secondary to childhood trauma significantly
increase vulnerability to the lifetime stress reactivity and subsequent
risk for the onset of depressive episodes (Heim et al., 2008, Nemeroff
and Binder, 2014), our findings suggest that development of depression
in adults exposed to early life trauma, is associated with increased HPA
axis activation in the context of glucocorticoid resistance. Coexistence
of hypercortisolemia and inflammatory biomarkers represents in-
sufficient glucocorticoid signalling in this subgroup of patients probably
due to impairment in GR functioning. Direct evaluation of GR func-
tional properties has been extensively studied in depression and in re-
lation to antidepressants treatment. With regards to early life stress and
future development of depression, there is evidence from genetic stu-
dies on the association of polymorphisms in genes regulating the HPA
axis and GR with depression and childhood trauma (Bet et al., 2009,
Heim and Binder, 2012, Roy et al., 2010). Epigenetic studies also have
shown a decrease hippocampal GR expression in animal models
(Meaney and Szyf, 2005) and in abused suicide victims (McGowan
et al., 2009).
To our knowledge this study is the first to investigate measures of
HPA axis and inflammation in the context of glucocorticoid resistance
in relation to childhood trauma, depression and treatment response in
the same population. The large sample size confirms validity of findings
from other smaller studies, which also investigated only some of these
pathophysiological disturbances. Despite a comprehensive assessment,
there are few limitations need to be mentioned. Firstly, patients were
not stratified according to depression subtypes. Based on the evidence
atypical depression may not be associated with HPA axis hyperactivity
and hypercortisolemia, which are observed in melancholic depressive
subtype (Juruena et al., 2018). In addition, since this is a cross-sectional
study, future longitudinal studies are needed to confirm our findings.
Finally, we only measured indirectly glucocorticoid resistance, where
high cortisol and high CRP provide the evidence for glucocorticoid
resistance, and therefore, an evaluation of GR function both by in vivo
assessment on the HPA axis (dexamethasone suppression test) and in
vitro measurements on blood immune cells (dexamethasone-inhibition
of LPS-induced cytokine levels) in future studies are needed to confirm
an impairment of the GR-mediated glucocorticoid resistance. It would
be also valuable for future studies to evaluate other inflammatory
markers which have been associated with both childhood trauma and
depression, as well to investigate potential differential effects of anti-
depressant on immune processes.
5. Conclusion
Although we found a link between childhood trauma and non-re-
sponse to the antidepressant treatment in our depressed patients, we
did not find specific evidence of HPA axis hyperactivity or glucocorti-
coid resistance in our treatment non-responder patients. However, our
results showed that untreated depressed patients had increased diurnal
cortisol and a higher prevalence of glucocorticoid resistance when
compared with depressed patients on antidepressant medication. Our
study shows that severity of childhood trauma contributes to increased
HPA axis hyperactivity specifically in patients who present glucocorti-
coid resistance. These findings support a role of glucocorticoid re-
sistance in amplifying the effects of childhood trauma in activating the
HPA axis and suggest glucocorticoid resistance as a target for the de-
velopment of personalised treatment for a subgroup of depressed pa-
tients with a history of childhood trauma rather than for all patients
with resistance to antidepressant treatment. Future studies should in-
vestigate alternative or adjuvant treatment strategies that may improve
glucocorticoid signalling in affected individuals and thereby reduce
both inflammation and depressive symptoms.
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